Bluebird Bio is a leading biotechnology company based in Cambridge, MA, dedicated to developing curative gene therapies for patients and their families. With a focus on diseases such as Beta-Thalassemia, Cerebral Adrenoleukodystrophy, and Sickle Cell Disease, Bluebird Bio utilizes its extensive ex-vivo gene therapy data set to drive advancements in the field and set the standard for gene therapy.
Through their proprietary lentiviral vector gene therapies, Bluebird Bio aims to deliver functional copies of genes to a patient's own cells, providing one-time treatments that offer the potential for long-lasting results. With a commitment to collaboration, ethical practices, and patient advocacy, Bluebird Bio is dedicated to delivering more "bluebird days" to patients and making a positive impact in the field of gene therapy.
Generated from the website